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Dose Escalation of Desmoteplase for Acute Ischemic
Stroke (DEDAS)
Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset
Anthony J. Furlan, MD; Dirk Eyding, PhD; Gregory W. Albers, MD; Yasir Al-Rawi, MD;
Kennedy R. Lees, MD; Howard A. Rowley, MD; Christian Sachara; Mariola Soehngen, MD;
Steven Warach, MD, PhD; Werner Hacke, MD; for the DEDAS Investigators
Background and Purpose—Desmoteplase is a novel plasminogen activator with favorable features in vitro compared
with available agents. This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with
perfusion/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke.
Methods—DEDAS was a placebo-controlled, double-blind, randomized, dose-escalation study investigating doses of 90
g/kg and 125 g/kg desmoteplase. Eligibility criteria included baseline National Institute of Health Stroke Scale
(NIHSS) scores of 4 to 20 and MRI evidence of perfusion/diffusion mismatch. The safety end point was the rate of
symptomatic intracranial hemorrhage. Primary efficacy co-end points were MRI reperfusion 4 to 8 hours after treatment
and good clinical outcome at 90 days. The primary analyses were intent-to-treat. Before unblinding, a target population,
excluding patients violating specific MRI criteria, was defined.
Results—Thirty-seven patients were randomized and received treatment (intent-to-treat; placebo: n8; 90 g/kg: n14;
125 g/kg: n15). No symptomatic intracranial hemorrhage occurred. Reperfusion was achieved in 37.5% (95% CI
[8.5; 75.5]) of placebo patients, 18.2% (2.3; 51.8) of patients treated with 90 g/kg desmoteplase, and 53.3% (26.6;
78.7) of patients treated with 125 g/kg desmoteplase. Good clinical outcome at 90 days occurred in 25.0% (3.2; 65.1)
treated with placebo, 28.6% (8.4; 58.1) treated with 90 g/kg desmoteplase and 60.0% (32.3; 83.7) treated with 125
g/kg desmoteplase. In the target population (n25), the difference compared with placebo increased and was
statistically significant for good clinical outcome with 125 g/kg desmoteplase (P0.022).
Conclusions—Treatment with IV desmoteplase 3 to 9 hours after ischemic stroke onset appears safe. At a dose of 125
g/kg desmoteplase appeared to improve clinical outcome, especially in patients fulfilling all MRI criteria. The results
of DEDAS generally support the results of its predecessor study, Desmoteplase in Acute Ischemic Stroke (DIAS).
(Stroke. 2006;37:1227-1231.)
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Intravenous (IV) thrombolytic treatment of acute ischemicstroke is currently limited to recombinant tissue plasmin-
ogen activator (rt-PA) within 3 hours after symptom onset.1 A
pooled analysis of all IV rt-PA stroke studies suggests a
benefit for treatment delays of up to 4.5 hours.2 All of these
studies used routine brain computed tomography (CT) for
patient selection.
Newer imaging technologies suggest that salvageable brain
may be present for several hours in many patients with acute
stroke.3–6 Desmoteplase (rDSPA1) is a novel plasminogen
activator with favorable features compared with available
agents including high fibrin specificity, long half life, and
lack of neurotoxicity or -amyloid activation in animal
models of stroke.7–9 The Desmoteplase in Acute Ischemic
Stroke Study (DIAS)10 was the first clinical study to select
patients for IV thrombolysis up to 9 hours after stroke onset
based on mismatch of perfusion-weighted/diffusion-weighted
(DWI) MRI. DIAS reported a low rate of symptomatic intracra-
nial hemorrhage (sICH) and evidence of reperfusion and clinical
efficacy using this agent and imaging approach. The Dose
Escalation of Desmoteplase in Acute Stroke (DEDAS) study
further evaluated safety and efficacy of IV desmoteplase in
patients with perfusion/diffusion mismatch 3 to 9 hours after
stroke onset.
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Patients and Methods
Methods and procedures of DEDAS were largely identical to
DIAS.10 Specifics of DEDAS and a brief overview are reported here.
Patients and Desmoteplase Dosages
Between March 2003 and October 2004, 21 centers in the US and 4
centers in Germany participated in DEDAS. The protocol and all
amendments received Institutional Review Board approval at each
center, and written informed consent was obtained from all patients
or their legal representatives.
DEDAS was a randomized, placebo-controlled, bodyweight-adjusted
dose-escalation study. Doses of 90 g/kg and 125 g/kg desmote-
plase were evaluated. Each dose tier included 15 desmoteplase
patients and 4 placebo patients. The sample size per dose tier was
fixed as  0.20 (probability of falsely regarding desmoteplase as
unsafe) and  0.40 (power of 60% for detecting an unacceptably high
rate of ICH 20%). No stratification was implemented. An inde-
pendent Data Monitoring Committee (IDMC) monitored hemor-
rhages and other adverse events using prospectively defined stopping
rules. Progression to the next dose tier was based on the recommen-
dation of the IDMC.
Patients were randomized to desmoteplase or placebo via an
interactive voice response system. Study drug was administered as
an IV bolus over 1 to 2 minutes. The IDMC was immediately
informed of each newly randomized patient, any hemorrhages, and
the 72-hour outcome of each patient. It was unblinded and not
involved in other study tasks.
Main Inclusion Criteria
Criteria included subjects age 18 through 85 years, and stroke onset
was within 3 through 9 hours; baseline National Institute of Health
Stroke Scale (NIHSS) score was 4 through 20. There was at least
20% perfusion/diffusion mismatch with a perfusion deficit, with or
without DWI lesion, of 2 cm in diameter and involving the cerebral
cortex on baseline. MRI inclusion was based on investigator visual
readings of MRI; quantitative analyses of lesion volume were based
on blinded central imaging readings (Perceptive Informatics, Inc).
Briefly, perfusion-weighted imaging and DWI sequences were ob-
tained in DICOM format and converted for planimetric analysis
using ALICE software. Lesion borders were drawn and volumes were
then calculated for the entire lesion. (A comprehensive description of
MRI acquisition and analyses will be separately communicated.)
Exclusion criteria were similar to those adopted by other thrombolytic
studies including any hemorrhage on baseline CT. Internal carotid
artery (ICA) occlusions without coexisting separate occlusion of the
middle cerebral artery were excluded, because of the difficulty
distinguishing between chronic and acute ICA lesions in such
patients.
Imaging Examinations
MRI was performed at screening, 4 to 8 hours post-treatment and at
30 days follow-up. CT was performed at 24 hours in all patients to
document any intracranial bleeding.
Safety End Points
The primary safety end point was the rate of sICH, defined as any
CT-confirmed ICH associated with a worsening of 4 points on the
NIHSS within 72 hours of treatment. Other safety outcomes included
mortality, anaphylaxis and major systemic bleeding, defined as a
bleeding considered life-threatening, the requirement to administer 2
or more units of packed red blood cells or a hemoglobin-drop by 40
g/L or more. Other adverse events and serious adverse events were
also monitored.
Efficacy End Points
The coprimary efficacy end points were reperfusion at 4 to 8 hours
and clinical outcome at 90 days. Physiologically relevant reperfusion
was defined as either 30% reduction of mean-transit-time volume
of abnormality or 2 points improvement on the adapted Throm-
bolysis in Myocardial Infarction (TIMI) scale on magnetic resonance
angiography. Good clinical outcome was a composite end point
defined as 8 points improvement or scoring 0 to 1 on the NIHSS,
a score of 0 to 2 on the modified Rankin Scale, and a Barthel Index
score of 75 to 100 at 90 days.
Analyses
The primary analysis was intent-to-treat (ITT). In addition, a target
population (TP) was defined before unblinding, which included only
patients who had MRI mismatch and no isolated ICA occlusion as
determined by the core laboratory.
Concomitant Medication
In the first 24 hours after administration of study drug, anticoagu-
lants and antiplatelet agents were not allowed. Use of other
thrombolytics was prohibited in the first 72 hours.
Results
The ITT population comprised 37 patients who were random-
ized and received treatment with study drug (placebo n
8, desmoteplase 90 g/kg n14, desmoteplase 125 g/kg
n15). One additional patient was withdrawn after random-
zation but before drug administration because of nonfulfill-
ment of MRI criteria.
The desmoteplase and placebo groups were balanced with
regard to age but not for time after onset (longer in the 90
g/kg dose group), baseline DWI lesion volumes (larger in
placebo), and baseline NIHSS (highest in placebo; Table 1).
Stroke etiologies were similar in all subgroups.
Twelve randomized patients were later determined by the
central imaging laboratory to have violated MRI criteria. Six
patients had isolated ICA occlusion and another 6 had either
no mismatch or no perfusion deficit. Six violations occurred
in the 90 g/kg dose group, 4 in the 125 g/kg group, and 2
in placebo. Hence, the TP sample size was n6 for placebo,
n8 for 90 g/kg and n11 for 125 g/kg (in total: n25).
TABLE 1. Characteristics of Patients (ITT population)
Placebo, (n8)
Desmoteplase 90 g/kg‡,
(n14)
Desmoteplase 125 g/kg‡,
(n15)
Desmoteplase‡,
(n29)
Total,
(n37)
Female* 37.5% 42.9% 46.7% 44.8% 43.2%
Age†, y 71.5 42–85 74.5 57–85 72 42–84 73 42–85 73 42–85
NIHSS† 12 6–18 10 4–18 9 5–19 9 4–19 11 4–19
Time after onset†, min 443 220–516 477 393–568 420 222–531 449 222–568 446 220–568
DWI lesion volume†, mL 35.1 1.5–68.6 25.3 1.6–73.0 20.7 4.1–78.1 22.2 1.6–78.1 22.7 1.5–78.1
Glucose level†, mmol/L 6.16 5.66–9.05 6.27 5.44–15.76 6.16 5.44–15.76 6.27 4.66–15.76 6.27 4.66–15.76
*Proportion of patients; †Median Range; ‡All values not significantly different from placebo.
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Safety
Primary Safety End Point
No symptomatic ICHs were observed.
Other Safety End Points
Three deaths occurred within 90 days, 1 from each treatment
group. The placebo patient died at day 5 secondary to stroke
progression. The patient in the 90 g/kg group died at day 53
secondary to an aspiration pneumonia. The patient in the 125
g/kg group experienced evolution of left middle cerebral
artery infarction with neurological deterioration complicated
by pneumonia and died at day 15.
Twelve asymptomatic ICH were observed: in 12.5% of
placebo-treated patients (n1), and 35.7% (n5) and 40.0%
(n6) of patients treated with 90 g/kg or 125 g/kg,
respectively. Nine were present on the routine 24-hour CT, 2 on
delayed 24-hour CT before 72 hours and 1 on an unscheduled
CT on day 15. Major systemic hemorrhage occurred in 12.5%
(n1) of placebo patients and 14.3% (n2) and 13.3% (n2) of
patients treated, respectively, with 90 g/kg and 125 g/kg
desmoteplase. Six of 11 asymptomatic ICH occurred in pa-
tients with MRI violations. No anaphylactic reactions oc-
curred (Table 2).
Efficacy
Reperfusion (ITT)
MR images of 3 patients treated with 90 g/kg desmoteplase
were either missing or not assessable. Early reperfusion at 4
to 8 hours after treatment occurred in 3 placebo-treated
patients (37.5%), in 2 patients (18.2%) in the 90 g/kg group,
and in 8 patients (53.3%) in the 125 g/kg group (Table 3,
Figure, a); neither of the desmoteplase groups reached statis-
tical superiority over placebo.
Primary Clinical End Point (ITT)
Good outcome at 90 days occurred in 2 (25.0%), 4 (28.2%)
and 9 (60.0%) patients in the placebo, 90 g/kg and 125
g/kg desmoteplase groups, respectively (Table 3, Figure, a).
The clinical outcome in the 125 g/kg group showed a trend
toward superiority over placebo (odds ratio [OR]4.50; 95%
CI: 0.67; 30.23; P0.06).
TP: Reperfusion
Compared with the ITT population, the reperfusion rate in the
TP increased for the 125 g/kg group (63.6%, n7), but
decreased for placebo (33.3%, n2) and for 90 g/kg
(16.7%, n1). The higher reperfusion rate of the 125 g/kg
group did not reach statistical significance over placebo
(OR3.50; 95% CI: 0.43; 28.45; P0.12 (Table 3, Figure, b).
Among patients with MRI protocol violations, the overall
reperfusion rate was 27.3% (1 of 2 in the placebo group; 1 of
5 in the desmoteplase 90 g/kg group and 1 of 4 in the 125
g/kg group).
TP: Primary Clinical End Point
The rate of good clinical outcome increased for the desmote-
plase groups, 37.5% (n3) for 90 g/kg and 72.7% (n8) for
the 125 g/kg group, but decreased for placebo (16.7%, n1)
when MRI violators were excluded. In the TP, clinical
outcome in the 125 g/kg group was statistically superior to
placebo (OR13.33; 95% CI: 1.07; 166.37; P0.022) but
not in the 90 g/kg group (OR3.00; 95% CI: 0.23; 39.61;
P0.20; Table 3, Figure, b).
Among patients with MRI protocol violations, a good
clinical outcome was observed in 1 of 2 receiving placebo,
and in 20.0% of patients treated with desmoteplase (1 of 6
receiving 90 g/kg and 1 of 4 receiving 125 g/kg).
Additional Analyses: Time Window
There was a positive correlation (Spearman 0.35; P0.03)
between baseline NIHSS and time from symptom onset,
mainly caused by a few less severe strokes in the 3- to 6-hour
time window, in the desmoteplase 125 g/kg group. The
majority of patients, however, were randomized in the 6- to
9-hour window (n28). Analysis restricted to the 6- to 9-hour
window showed a random distribution of stroke severity
(Spearman 0.08) and eliminated the imbalance in baseline
NIHSS and DWI lesion volume. A separate 3- to 6-hour
analysis was not done attributable to the small (n9) sample
TABLE 2. Safety (ITT population)
Placebo,
(n8)
Desmoteplase 90 g/kg,
(n14)
Desmoteplase 125 g/kg,
(n15)
Desmoteplase,
(n29)
Total,
(n37)
Symptomatic ICH*‡ 0 (0; 0; 36.9) 0 (0; 0; 23.2) 0 (0; 0; 21.8) 0 (0; 0; 11.9) 0 (0; 0; 9.5)
Asymptomatic ICH* 1 (12.5; 0.3; 52.7) 5 (35.7; 12.8; 64.9) 6 (40.0; 16.3; 67.7) 11 (37.9; 20.7; 57.7) 12 (32.4; 18.0; 49.8)
OR vs placebo† 3.89 0.37; 41.32 4.67 0.45; 48.26 4.28 0.46; 39.6
P0.13 P0.098 P0.100
Mortality* 1 (12.5; 0.3; 52.7) 1 (7.1; 0.2; 33.9) 1 (6.7; 0.2; 31.9) 2 (6.9; 0.8; 22.8) 3 (8.1; 1.7; 21.9)
OR vs placebo† 0.54 0.03; 9.99 0.50 0.03; 9.24 0.52 0.04; 6.58
P0.66 P0.68 P0.69
Major systemic
bleeding*
1 (12.5; 0.3; 52.7) 2 (14.3; 1.8; 42.8) 2 (13.3; 1.7; 40.5) 4 (13.8; 3.9; 31.7) 5 (13.5; 4.5; 28.8)
OR vs placebo† 1.17 0.09; 15.32 1.08 0.08; 14.08 1.12 0.11; 11.70
P0.45 P0.48 P0.46
Anaphylactic reaction*‡ 0 (0; 0; 36.9) 0 (0; 0; 23.2) 0 (0; 0; 21.8) 0 (0; 0; 11.9) 0 (0; 0; 9.5)
*No. of patients (%; 95% CI); †OR; 95% CI; P value (OR1); ‡No OR calculated (division by 0).
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size. Reperfusion and good clinical outcomewere observed in
62.5% (5 of 8) and 50.0% (4 of 8) of patients who received
desmoteplase 125 g/kg 6 to 9 hours after symptom onset
despite a higher median baseline NIHSS (14) and age (median
age77.5 years) compared with the ITT (3 to 9 hours) group.
Change in Lesion Volume
Median T2 lesion volume increased in all treatment groups
from baseline to day 30. The median increase in lesion
volume was smallest in the desmoteplase 125 g/kg group
(28.6%), but was not significantly different from the median
increase (39.2%) in placebo patients.
Reperfusion and Clinical Outcome
Reperfusion was highly correlated with good clinical out-
come. In the 34 patients with assessable MR images, 69.2%
(9/13) of patients with reperfusion had a good clinical
outcome at 90 days compared with 19.0% (4/21) without
reperfusion (P0.003).
Discussion
DEDAS provides further evidence that IV thrombolysis with
desmoteplase 3 to 9 hours after stroke onset at doses of 90
g/kg and 125 g/kg is safe with a low rate of sICH in patients
selected by perfusion/diffusion mismatch on MRI. Reperfusion
on MRI was strongly correlated with good clinical outcome and
appeared improved with 125 g/kg IV desmoteplase.
The in vitro properties of desmoteplase theoretically con-
tribute to a low rate of sICH, enhanced reperfusion and
possibly a low rate of reocclusion. Perfusion brain imaging
further helps to optimize safety and patient selection for
thrombolysis beyond 3 hours after stroke onset. The results of
DIAS,10 supported now by DEDAS, are consistent with these
hypotheses. In the combined studies there has been only 1
sICH out of 59 patients treated with either 90 g/kg or 125
g/kg desmoteplase, whereas MRI has provided physiologi-
cal evidence of reperfusion efficacy, especially with 125
g/kg. The rate of asymptomatic ICH, often a marker of
reperfusion,11 was increased in desmoteplase patients but was
consistent with other thrombolysis studies, including DIAS.10
TABLE 3. Efficacy
Reperfusion 4–8 hours After Treatment*
Placebo Desmoteplase 90 g/kg Desmoteplase 125 g/kg Desmoteplase Total
ITT
n8
TP
n6
ITT
n11
TP
n6
ITT
n15
TP
n11
ITT
n26
TP
n17
ITT
n34
TP
n23
No. (%) 3 (37.5) 2 (33.3) 2 (18.2) 1 (16.7) 8 (53.3) 7 (63.6) 10 (38.5) 8 (47.1) 13 (38.2) 10 (43.5)
95% CI 8.5; 75.5 4.3; 77.7 2.3; 51.8 0.4; 64.1 26.6; 78.7 30.8; 89.1 20.2; 59.4 23.0; 72.2 22.2; 56.4 23.2; 65.5
OR vs placebo 0.37 0.40 1.90 3.50 1.04 1.78
95% CI 0.05; 3.01 0.03; 6.18 0.33; 11.01 0.43; 28.45 0.20; 5.34 0.25; 12.45
P value
(OR1)
P0.82 P0.74 P0.24 P0.12 P0.48 P0.28
Good Clinical Outcome 90 Days After Treatment†
n8 n6 n14 n8 n15 n11 n29 n19 n37 n25
No. (%) 2 (25.0) 1 (16.7) 4 (28.6) 3 (37.5) 9 (60.0) 8 (72.7) 13 (44.8) 11 (57.9) 15 (40.5) 12 (48.0)
95% CI 3.2; 65.1 0.4; 64.1 8.4; 58.1 8.5; 75.5 32.3; 83.7 39.0; 94.0 26.4; 64.3 33.5; 79.7 24.8; 57.9 27.8; 68.7
OR vs placebo 1.20 3.00 4.50 13.33 2.44 6.88
95% CI 0.17; 8.66 0.23; 39.61 0.67; 30.23 1.07; 166.4 0.42; 14.16 0.67; 70.82
P value
(OR1)
P0.43 P0.20 ‡P0.061 ‡‡P0.022 P0.16 P0.053
*Patients with assessable images; Reperfusion defined as30% reduction in MTT volume of abnormality OR2 points improvement on adapted TIMI scale. †Good
Outcome defined as 8 points NIHSS improvement (or final value 1) AND modified Rankin Scale 2 AND Barthel Index 75; ‡trend towards statistical superiority
over placebo (efficacy 4.5 higher than placebo); ‡‡statistical superiority over placebo.
Univariate ORs over placebo regarding reperfusion (gray bars)
and good clinical outcome after 90 days (black bars). a, Results
of the ITT population. b, Results of the TP.
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As opposed to DIAS,10 in DEDAS reperfusion in desmote-
plase patients did not reach statistical significance compared
with placebo although there was a strong trend with 125
g/kg. The absence of reperfusion in the 90 g/kg group
(18.2%) is also discordant with DIAS (46.7%). These differ-
ences may relate to the higher reperfusion rate in the placebo
group in DEDAS (37.5%) compared with DIAS (19.2%)
which might reflect the small sample size, or differences in
sites of occlusion and collateral flow between the 2 studies.
The higher rates of nonassessable images and MRI protocol
violations in DEDAS may also have impacted on the 90
g/kg results. Detailed combined imaging analyses will be
reported separately.
For clinical outcome, there was no difference between
placebo and the 90 g/kg dose. Clinical outcome in the 125
g/kg group was substantially better than placebo (ITT: 35%
absolute difference), reaching the level of DIAS. Again,
statistical significance was not reached possibly because of
the small sample size. The clinical response rate of the 125
g/kg group in DEDAS may also represent an overestimation
attributable to an excess of less severely affected patients
compared with placebo. However, the NIHSS imbalance was
not present when the analysis was restricted to the 6- to
9-hour time window, yet the improved clinical outcome for
the 125 g/kg group relative to placebo remained. The TP
analysis also provides supporting evidence for the main study
hypotheses. Reperfusion and clinical response rates of the
target patients treated with 125 g/kg desmoteplase increased
compared with ITT, whereas the response rates of the MRI
protocol violators treated with desmoteplase were low. The 6-
to 9-hour time window analysis suggests that the presence of
perfusion/diffusion mismatch as a marker of tissue at risk
may be a more important predictor of therapeutic response
than duration of symptoms. Furthermore, as in DIAS,10 there
was a strong positive correlation (P0.003) between reper-
fusion and good clinical outcome, which is consistent with a
recent report of patients receiving IV rt-PA, which found that
a decrease in the volume of pretreatment mean-transit-time
defect by 30% or greater 2 to 3 hours after treatment was a
highly significant predictor of clinical recovery.12
DIAS and DEDAS provide preliminary evidence that 125
g/kg is a safe and effective dose of desmoteplase in patients
with perfusion/diffusion mismatch on MRI up to 9 hours
from stroke onset. If confirmed in the ongoing DIAS-2 study,
the combination of perfusion imaging with IV desmoteplase
may change the imaging paradigm in acute stroke and
increase the number of potentially treatable patients.
Appendix
The following centers recruited patients to DEDAS (Center, Princi-
pal Investigator and number of patients): US-Cleveland, OH: Sila
(7), US-Madison, WI: Newman (7), US-Chattanooga, TN: Devlin (6),
US-Nashville, TN: Kaminski (3), US-Los Angeles, CA: Starkman (2),
US-Louisville, KY: Remmel (2), D-Leipzig: Schneider (2), US-New
Hyde Park, NY: Libman (1), US-Great Falls, MT: Dietrich (1),
US-Stony Brook, NY (1), US-Boston, MA: Selim (1), US-Kansas City,
KA: Dafer (1), US-Dallas, TX: Unwin (1), US-Lexington, KY: Petti-
grew (1), D-Heidelberg: Hacke and Ringleb (1), D-Ulm: Huber (1).
Steering Committee: Anthony Furlan (Chair), Werner Hacke,
Howard Rowley, Steven Warach, Greg Albers, Michael Fischer,
Mariola Soehngen, Yasir Al-Rawi.
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